CoChat
Sign Up
Cited by 158Cervical Cancer and HPV ResearchEndometrial and Cervical Cancer TreatmentsBreast Cancer Treatment Studies

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer

Open access
Lyng, Heidi, Brøvig, Runar S, Svendsrud, Debbie H, Holm, Ruth, Kaalhus, Olav, Knutstad, Kjetil, Oksefjell, Halldis, Sundfør, Kolbein, Kristensen, Gunnar B, Stokke, Trond·2006·BMC Genomics
DOI 10.1186/1471-2164-7-268PMC PMC1626467
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: A better understanding of the development of metastatic disease and the identification of molecular markers for cancer spread would be useful for the design of improved treatment strategies. This study was conducted to identify gene expressions associated with metastatic phenotypes of locally advanced cervical carcinomas and investigate whether gains or losses of these genes could play a role in regulation of the transcripts. Gene expressions and copy number changes were determined in primary tumors from 29 patients with and 19 without diagnosed lymph node metastases by use of cDNA and genomic microarray techniques, respectively. RESULTS: Thirty-one genes that differed in expression between the node positive and negative tumors were identified. Expressions of eight of these genes (MRPL11, CKS2, PDK2, MRPS23, MSN, TBX3, KLF3, LSM3) correlated with progression free survival in univariate analysis and were therefore more strongly associated with metastatic phenotypes than the others. Immunohistochemistry data of CKS2 and MSN showed similar relationships to survival. The prognostic genes clustered into two groups, suggesting two major metastatic phenotypes. One group was associated with rapid proliferation, oxidative phosphorylation, invasiveness, and tumor size (MRPS23, MRPL11, CKS2, LSM3, TBX3, MSN) and another with hypoxia tolerance, anaerobic metabolism, and high lactate content (PDK2, KLF3). Multivariate analysis identified tumor volume and PDK2 expression as independent prognostic variables. Gene copy number changes of the differentially expressed genes were not frequent, but correlated with the expression level for seven genes, including MRPS23, MSN, and LSM3. CONCLUSION: Gene expressions associated with known metastatic phenotypes of cervical cancers were identified. Our findings may indicate molecular mechanisms underlying development of these phenotypes and be useful as markers of cancer spread. Gains or losses of the genes may be involved in development of the metastatic phenotypes in some cases, but other mechanisms for transcriptional regulation are probably important in the majority of tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2164-7-268

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Gene expressions and copy numbers in node negative and positive tumors. A, Expression ratios of 31 genes that differed in expression between 19 node negative and 29 node positive cervical tumors. The data are the average log2ratio of two dye-swap experiments. Gene symbols (NCBI UniGene) are shown to the right. The genes indicated with a dark blue line were upregulated in node positive compared to node negative tumors, whereas those marked light blue were downregulated. The ratios were median centered, and expressions higher and lower than the median expression of that gene are shown in red and green, respectively. The most intense colors represent log2ratios of > 2.0 (red) and < -2.0 (green) relative to the median, whereas black represents expression close to the median value. B, Gene copy number relative to modal DNA content (log2ratio) of the BAC clones covering or are close to the genes in (A) for the patients presented in (A). Patient P-058 is not included, since tumor DNA was not available. BAC clone identifications and the corresponding gene symbols (NCBI UniGene) are shown to the right. Gene gains and losses are shown in red and green, respectively, whereas black represents no aberration. The most intense red and green colors represent log2ratios of > 0.8 and < -0.8, respectively. The log2ratios varied between -0.84 and 2.19.
Figure 1 Gene expressions and copy numbers in node negative and positive tumors. A, Expression ratios of 31 genes that differed in expression between 19 node negative and 29 node positive cervical tumors. The data are the average log2ratio of two dye-swap experiments. Gene symbols (NCBI UniGene) are shown to the right. The genes indicated with a dark blue line were upregulated in node positive compared to node negative tumors, whereas those marked light blue were downregulated. The ratios were median centered, and expressions higher and lower than the median expression of that gene are shown in red and green, respectively. The most intense colors represent log2ratios of > 2.0 (red) and < -2.0 (green) relative to the median, whereas black represents expression close to the median value. B, Gene copy number relative to modal DNA content (log2ratio) of the BAC clones covering or are close to the genes in (A) for the patients presented in (A). Patient P-058 is not included, since tumor DNA was not available. BAC clone identifications and the corresponding gene symbols (NCBI UniGene) are shown to the right. Gene gains and losses are shown in red and green, respectively, whereas black represents no aberration. The most intense red and green colors represent log2ratios of > 0.8 and < -0.8, respectively. The log2ratios varied between -0.84 and 2.19.CC BY · PubMed Central
Figure 2 Gene copy numbers in relation to gene expressions. A, Gene copy number relative to model DNA content (log2ratio) versus position on chromosome 17 (left panel) and chromosome X (right panel), demonstrating gain of PDK2 and MRPS23 (chromosome 17) and loss of MSN (chromosome X) in two different cervical tumors. Each point represents the data for a BAC clone on the genomic microarray. For identification of gains and losses the relative copy number of neighboring clones was always considered in addition to that of the clone of interest. All amplified or deleted regions contained at least three clones. B, Gene expressions (absolute scale) in 47 tumors with loss, no aberration (normal), or gain of LSM3, ANXA4, MSN, MRPS23, FLJ13291, MBNL2, and MGC14151. These genes were the ones with a significant correlation between gene expression and copy number. The chromosomal location of the genes is listed in Table 1. Columns, mean values for all tumors in the groups; bars, standard errors. P-values for the correlations and number of tumors in each group are indicated.
Figure 2 Gene copy numbers in relation to gene expressions. A, Gene copy number relative to model DNA content (log2ratio) versus position on chromosome 17 (left panel) and chromosome X (right panel), demonstrating gain of PDK2 and MRPS23 (chromosome 17) and loss of MSN (chromosome X) in two different cervical tumors. Each point represents the data for a BAC clone on the genomic microarray. For identification of gains and losses the relative copy number of neighboring clones was always considered in addition to that of the clone of interest. All amplified or deleted regions contained at least three clones. B, Gene expressions (absolute scale) in 47 tumors with loss, no aberration (normal), or gain of LSM3, ANXA4, MSN, MRPS23, FLJ13291, MBNL2, and MGC14151. These genes were the ones with a significant correlation between gene expression and copy number. The chromosomal location of the genes is listed in Table 1. Columns, mean values for all tumors in the groups; bars, standard errors. P-values for the correlations and number of tumors in each group are indicated.CC BY · PubMed Central
Figure 3 Protein expressions in relation to gene expressions. Immunostaining of CKS2 (nuclear), MSN (membrane/cytoplasmic), CSTA (nuclear/cytoplasmic), MEF2A (nuclear/cytoplasmic), and HK2 (cytoplasmic) in cervical tumors with high protein levels (left panels) and immunostaining score in 48 cervical tumors with low or high gene expression of CKS2, MSN, CSTA, MEF2A, and HK2 (right panels). MSN, MEF2A, and HK2 were expressed in both tumor and stroma cells, and only the immunostaining in tumor cells is included in the histograms. For CKS2 and CSTA, which were upregulated in node positive tumors, the histograms compares the immunostaining score between the quartile of tumors (n = 12) with the highest gene expression and the remaining 36 ones. For HK2, MEF2A, and MSN, which were downregulated in node positive tumors, the immunostaining score between the quartile of tumors with lowest gene expression and the remaining 36 ones is compared. Columns, mean values for all tumors in the groups; bars, standard errors. P-values for the correlations are indicated.
Figure 3 Protein expressions in relation to gene expressions. Immunostaining of CKS2 (nuclear), MSN (membrane/cytoplasmic), CSTA (nuclear/cytoplasmic), MEF2A (nuclear/cytoplasmic), and HK2 (cytoplasmic) in cervical tumors with high protein levels (left panels) and immunostaining score in 48 cervical tumors with low or high gene expression of CKS2, MSN, CSTA, MEF2A, and HK2 (right panels). MSN, MEF2A, and HK2 were expressed in both tumor and stroma cells, and only the immunostaining in tumor cells is included in the histograms. For CKS2 and CSTA, which were upregulated in node positive tumors, the histograms compares the immunostaining score between the quartile of tumors (n = 12) with the highest gene expression and the remaining 36 ones. For HK2, MEF2A, and MSN, which were downregulated in node positive tumors, the immunostaining score between the quartile of tumors with lowest gene expression and the remaining 36 ones is compared. Columns, mean values for all tumors in the groups; bars, standard errors. P-values for the correlations are indicated.CC BY · PubMed Central
Figure 4 Progression free survival analysis. Kaplan Meier plots of progression free survival for 48 cervical cancer patients with high or low gene expression of MRPS23, PDK2, CKS2, and MSN (A), with loss, gain, or no change in gene copy number of MRPS23, PDK2, and MSN (B), and with high or low protein expression of CKS2 and MSN in the tumor cells (C). Number of patients in each group and p-value in log rank test are indicated. The p-values in (A) differ slightly from that in Table 2 because log-rank tests are used in (A), whereas the data in Table 2 are based on Cox regression analysis. Note the concordance in the results based on gene expressions, copy numbers, and protein expressions.
Figure 4 Progression free survival analysis. Kaplan Meier plots of progression free survival for 48 cervical cancer patients with high or low gene expression of MRPS23, PDK2, CKS2, and MSN (A), with loss, gain, or no change in gene copy number of MRPS23, PDK2, and MSN (B), and with high or low protein expression of CKS2 and MSN in the tumor cells (C). Number of patients in each group and p-value in log rank test are indicated. The p-values in (A) differ slightly from that in Table 2 because log-rank tests are used in (A), whereas the data in Table 2 are based on Cox regression analysis. Note the concordance in the results based on gene expressions, copy numbers, and protein expressions.CC BY · PubMed Central
Figure 5 Cluster analysis of genes and patients. A, Cluster diagram of MSN, TBX3, LSM3, CKS2, MRPL11, MRPS23, KLF3, and PDK2 expression in 19 node negative and 29 node positive cervical tumors. B, Cluster diagram of 48 cervical tumors based on MSN, TBX3, LSM3, CKS2, MRPL11, and MRPS23 expression (left) and Kaplan Meier plots of progression free survival for patients in group 1 and 4 (high expression of MRPL11, MRPS23, CKS2, and LSM3 and low expression of MSN and TBX3) versus group 2 and 3 (low expression of MRPL11, MRPS23, CKS2, and LSM3 and high expression of MSN and TBX3) (right). C, Cluster diagram of 48 cervical tumors based on KLF3 and PDK2 expression (left) and Kaplan Meier plots of progression free survival for patients in group 1 (high expression of KLF3 and low expression of PDK2) versus groups 2 (low expression of KLF3 and high expression of PDK2) (right). Clustering was performed based on the log2ratios, using absolute Pearson correlation (A) or Pearson correlation (B, C) algorithms. The ratios were median centered, and expressions higher and lower than the median expression of that gene are shown in red and green, respectively. The most intense colors represent log2ratios of > 1.0 (red) and < -1.0 (green) relative to the median value, whereas black represents expression close to median. Arrows point to patients with gain of MRPS23 and PDK2 (red) or loss of MSN (green). Group numbers and p-value in log rank test are indicated in the Kaplan Meier plots.
Figure 5 Cluster analysis of genes and patients. A, Cluster diagram of MSN, TBX3, LSM3, CKS2, MRPL11, MRPS23, KLF3, and PDK2 expression in 19 node negative and 29 node positive cervical tumors. B, Cluster diagram of 48 cervical tumors based on MSN, TBX3, LSM3, CKS2, MRPL11, and MRPS23 expression (left) and Kaplan Meier plots of progression free survival for patients in group 1 and 4 (high expression of MRPL11, MRPS23, CKS2, and LSM3 and low expression of MSN and TBX3) versus group 2 and 3 (low expression of MRPL11, MRPS23, CKS2, and LSM3 and high expression of MSN and TBX3) (right). C, Cluster diagram of 48 cervical tumors based on KLF3 and PDK2 expression (left) and Kaplan Meier plots of progression free survival for patients in group 1 (high expression of KLF3 and low expression of PDK2) versus groups 2 (low expression of KLF3 and high expression of PDK2) (right). Clustering was performed based on the log2ratios, using absolute Pearson correlation (A) or Pearson correlation (B, C) algorithms. The ratios were median centered, and expressions higher and lower than the median expression of that gene are shown in red and green, respectively. The most intense colors represent log2ratios of > 1.0 (red) and < -1.0 (green) relative to the median value, whereas black represents expression close to median. Arrows point to patients with gain of MRPS23 and PDK2 (red) or loss of MSN (green). Group numbers and p-value in log rank test are indicated in the Kaplan Meier plots.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. NCBI UniGene database. [ http://www.ncbi.nlm.nih.gov/UniGene ]

Cited by

Sorted by citations

See all 158

Related

See all

Metadata

Authors
Lyng, H., Brøvig, R. S., Svendsrud, D. H., Holm, R., Kaalhus, O., Knutstad, K., Oksefjell, H., Sundfør, K., Kristensen, G. B., & Stokke, T.
Affiliations
University of Oslo (NO)
Corresponding author
Lyng, Heidi
ORCID
Venue
BMC Genomics
Publisher
Springer Science and Business Media LLC
Published
2006-10-20
Volume
7
Issue
1
Pages
268-268
ISSN
1471-2164 (ISSN-L)
DOI
10.1186/1471-2164-7-268
PMC
PMC1626467
OpenAlex
W2170540646
Cited by
158
References
56
Citations by year
2026: 5 · 2025: 4 · 2024: 4 · 2023: 8 · 2022: 7 · 2021: 5 · 2020: 6 · 2019: 5 · 2018: 13 · 2017: 12 · 2016: 3 · 2015: 11 · 2014: 8 · 2013: 10 · 2012: 11
FWCI
5.39
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Genomics (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
Funders
Norges Forskningsråd
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
cervical cancer, lymph node metastasis, metastatic phenotype, gene expression, copy number alterations, prognostic genes, PDK2, MSN, CKS2, TBX3, KLF3, progression-free survival, tumor volume, hypoxia tolerance, oxidative phosphorylation, anaerobic metabolism, metastasis markers
MeSH terms
Analysis of Variance, Carcinoma, Squamous Cell, Carrier Proteins, Uterine Cervical Neoplasms, Female, Humans, Immunohistochemistry, Lymphatic Metastasis, Microfilament Proteins, Phenotype, Protein Kinases, Regression Analysis, Ribosomal Proteins, Gene Expression Regulation, Neoplastic, Cluster Analysis, Proportional Hazards Models, Survival Analysis, Protein Serine-Threonine Kinases, Gene Dosage, Cell Cycle Proteins, Oligonucleotide Array Sequence Analysis, T-Box Domain Proteins, Gene Expression Profiling, CDC2-CDC28 Kinases, Kruppel-Like Transcription Factors, 3-Phosphoinositide-Dependent Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review